Cat. #152937
Anti-C170 [NCRC22]
Cat. #: 152937
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 3-4 weeks
Target: C170 - Colorectal carcinoma cell line
Class: Monoclonal
Application: ELISA ; FACS
Reactivity: Human
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Lindy Durrant
Institute: University of Nottingham
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-C170 [NCRC22]
- Research fields: Cancer;Cell biology;Tags and cell markers
- Clone: [NCRC22]
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Strain: Balb/c
- Reactivity: Human
- Host: Mouse
- Application: ELISA ; FACS
- Description: Colorectal carcinoma is one of the most common malignant neoplasms. The cell line C170 was derived directly from a human primary tumor and as such was used as an immunogen to generate an antibody which is able to detect an epitope of a variety of colorectal cancerous cell lines.
- Immunogen: C170 cells
- Isotype: IgG1
- Myeloma used: P3NSI-Ag-1
- Recommended controls: Cell lines: C168, MKN45, HT29, A549, Colo205
Target Details
- Target: C170 - Colorectal carcinoma cell line
- Tissue cell line specificity: Cell lines: C168, MKN45, HT29, A549, Colo205
- Target background: Colorectal carcinoma is one of the most common malignant neoplasms. The cell line C170 was derived directly from a human primary tumor and as such was used as an immunogen to generate an antibody which is able to detect an epitope of a variety of colorectal cancerous cell lines.
Applications
- Application: ELISA ; FACS
Handling
- Format: Liquid
- Concentration: 0.9-1.1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15° C to -25° C
- Shipping conditions: Shipping at 4° C
References
- Durrant et al. 1986. Br J Cancer. 53(1):37-45. PMID: 3947514.
- Antigenicity of newly established colorectal carcinoma cell lines.
